Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.
Twenty-one patients with Parkinson's disease and psychosis were included in an open-label 8-week trial of olanzapine. Eight subjects had dementia. Six subjects (29%) discontinued treatment prematurely because of drowsiness. Delusions and hallucinations improved significantly, and 80% were rated as much or very much improved. There was no worsening of parkinsonism or cognition.
Aarsland
D
D
Section of Geriatric Psychiatry, Rogaland Psychiatric Hospital, Stavanger, Norway. aarsland@netpower.no
Larsen
J P
JP
Lim
N G
NG
Tandberg
E
E
D000368:Aged; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D003704:Dementia / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D009483:Neuropsychological Tests; D000077152:Olanzapine; D010300:Parkinson Disease / Q000150:complications*; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011446:Prospective Studies; D011618:Psychotic Disorders / Q000150:complications* / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine